Phospholipid-Protein Bioconjugates for Stable Autoantibody Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic methods for autoimmune disorders, such as antiphospholipid syndrome, face challenges with low chemical stability, selectivity, and high costs due to the use of heterogeneous phospholipid molecules from natural sources, leading to time-consuming and unreliable tests.

Innovation Solution

Development of novel phospholipid-peptide and phospholipid-protein conjugates with improved stability and selectivity, utilizing a 1,2,3-triazole linker and biologically complementary molecules like beta2-GPI and prothrombin, which are covalently bound via CuAAC or SPAAC click chemistry, enhancing binding affinity and specificity for autoimmune antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If heterogeneous phospholipid molecules from natural sources are used in diagnostic tests, then the tests can detect autoimmune antibodies, but the chemical stability is low and selectivity is poor

Engineering Contradiction:
Improvechemical stabilityVSAvoiddiagnostic test complexity
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of phospholipids through synthetic analogues with defined stereochemistry and purity. This transforms the heterogeneous natural phospholipids into homogeneous synthetic versions with improved chemical stability while maintaining immunogenicity for antibody detection

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite materials by conjugating phospholipids with carrier proteins (such as BSA, KLH, or lipoproteins) through stable linkers. This composite approach enhances the chemical stability and selectivity of the diagnostic reagents while enabling reliable detection of autoimmune antibodies

Inventive Principle:
Principle #40Composite materials

2Measurement precision

If heterogeneous phospholipid molecules from natural sources are used, then antibody detection is possible, but selectivity and sensitivity are low

Engineering Contradiction:
Improveantibody detection selectivityVSAvoidcost of diagnostic tests
Core Design Contradiction:
Measurement precisionVSQuantity of substance

Solution Approach 1:

The patent improves measurement precision by changing the purity and stereochemical definition parameters of phospholipid reagents. Synthetic phospholipid analogues with defined configurations provide superior selectivity for specific autoantibodies, reducing cross-reactivity and improving diagnostic accuracy

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by introducing specific modifications at particular positions of the phospholipid molecule (such as fatty acid chain composition, head group variations, or conjugation sites). These localized changes enhance antibody-binding specificity while maintaining overall molecular functionality

Inventive Principle:
Principle #3Local quality

3Reliability

If current diagnostic approaches with multiple separate tests are used, then comprehensive antibody detection is achieved, but time consumption and cost increase

Engineering Contradiction:
Improvedetection accuracyVSAvoiddiagnostic testing time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent merges multiple separate diagnostic tests into a single integrated assay by using phospholipid-protein conjugates that can simultaneously detect multiple autoantibody types. This consolidation maintains comprehensive detection capability while reducing the number of separate tests required, thereby saving time and reducing costs

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel conjugates demonstrate high stability upon storage and specificity in detecting autoimmune antibodies, offering improved diagnostic performance and potential therapeutic applications for autoimmune diseases.

Implementation Method 1

phospholipid and protein are biologically complementary, i.e. interact in vivo

Methodology Applied
Scientific EffectNon-covalent interaction: Van der Waals Force

Data Source

PatentEP3640642B1Novel artificial phospholipid-protein bioconjugates for biomolecular recognition
Publication Date: 2021.04.28 INTEGRATED BIOMEDICAL TECH APS
  • EP3640642B1 patent drawingFigure 1a~1b
  • EP3640642B1 patent drawingFigure 2
  • EP3640642B1 patent drawingFigure 3

AI summary

There is provided phospholipid-peptide or phospholipid-protein conjugates useful for identification of autoantibodies, and in particular autoantibodies directed towards phospholipids. There is further provided intermediates and methods for their preparation as well as synthesis of the phospholipid-peptide or phospholipid-protein conjugates.